Arthur Kavanaugh
Impact in
- Rheumatology top 0.02%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Immunology top 0.2%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Rheumatology 256
- Spondyloarthritis Studies and Treatments 199
- Rheumatoid Arthritis Research and Therapies 105
- Systemic Lupus Erythematosus Research 14
- Immunology 109
- Psoriasis: Treatment and Pathogenesis 97
- Co-authors
- Philip J. Mease (77 shared papers)Alice B. Gottlieb (28 shared papers)Christopher T. Ritchlin (39 shared papers)Iain B. McInnes (46 shared papers)Dafna D. Gladman (54 shared papers)L. Puig (19 shared papers)Proton Rahman (25 shared papers)Alan M. Mendelsohn (13 shared papers)
- Journals
- Annals of the Rheumatic Diseases (101 papers)The Journal of Rheumatology (27 papers)RMD Open (17 papers)Arthritis Research & Therapy (16 papers)Arthritis Care & Research (16 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Arthur Kavanaugh
309 papers receiving 12.7k citations
Arthur Kavanaugh's Hit Papers
Peers
Comparison fields: 5 of 131
- Rheumatology 8.5k
- Immunology 5.7k
- Hematology 2.7k
- Dermatology 966
- Complementary and Manual Therapy 81
Countries citing papers authored by Arthur Kavanaugh
This map shows the geographic impact of Arthur Kavanaugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur Kavanaugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur Kavanaugh more than expected).
Fields of papers citing papers by Arthur Kavanaugh
This network shows the impact of papers produced by Arthur Kavanaugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur Kavanaugh. The network helps show where Arthur Kavanaugh may publish in the future.
Co-authors
The 25 scholars most cited alongside Arthur Kavanaugh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 319 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 670 |
| 2 | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Hit paper breakdown → | 2013 | 638 |
| 3 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Hit paper breakdown → | 2014 | 530 |
| 4 | Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) Hit paper breakdown → | 2005 | 519 |
| 5 | Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial Hit paper breakdown → | 2009 | 470 |
| 6 | Treatment recommendations for psoriatic arthritis Hit paper breakdown → | 2008 | 428 |
| 7 | 2014 | 420 | |
| 8 | Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Hit paper breakdown → | 2014 | 353 |
| 9 | 2010 | 290 | |
| 10 | 2007 | 253 | |
| 11 | 2014 | 236 | |
| 12 | 2013 | 227 | |
| 13 | 2014 | 218 | |
| 14 | Psoriatic arthritis Hit paper breakdown → | 2021 | 216 |
| 15 | 2013 | 204 | |
| 16 | Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial Hit paper breakdown → | 2020 | 184 |
| 17 | 2016 | 179 | |
| 18 | 2010 | 178 | |
| 19 | 2012 | 172 | |
| 20 | 2006 | 164 |
About Arthur Kavanaugh
Arthur Kavanaugh is a scholar working on Rheumatology, Immunology, Hematology, Genetics and Pathology and Forensic Medicine, having authored 319 papers that have together received 13.2k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (199 papers), Rheumatoid Arthritis Research and Therapies (105 papers), Psoriasis: Treatment and Pathogenesis (97 papers), Autoimmune and Inflammatory Disorders Research (57 papers), Chronic Lymphocytic Leukemia Research (22 papers), Systemic Lupus Erythematosus Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Pharmaceutical studies and practices (8 papers). The work is most often cited by research in Rheumatology (8.5k citations), Immunology (5.7k citations), Hematology (2.7k citations), Dermatology (966 citations) and Complementary and Manual Therapy (81 citations). Arthur Kavanaugh has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Philip J. Mease, Alice B. Gottlieb, Christopher T. Ritchlin, Iain B. McInnes, Dafna D. Gladman, L. Puig, Proton Rahman, Alan M. Mendelsohn, Bruce Kirkham and Désirée van der Heijde. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, RMD Open, Arthritis Research & Therapy and Arthritis Care & Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.